Moderna is working on the development of a combined vaccine against corona, the flu and RSV virus
Posted on Jan 17, 2022 by Ifi Reporter
Moderna, the Company that developed the mRNA vaccine for the corona virus is working on the development of a combined vaccine against corona, the flu and RSV vi reported that the RSV vaccine trials are already in phase 3, while the flu trials are in phase 2 but are expected to move to phase 3 in the second quarter of the year.rus, which is another common virus that causes cold-like symptoms.
The company's CEO Stephen Bensel announced today that they hope to market the vaccine after it is approved in the fall of 2023. "One of the goals is to reach one annual booster so people will not have to get two or three shots each winter for flu, corona and RSV," the CEO said.
The CEO
Moderna's vaccine, like that of PfIZER -1.06% which was the main use in Israel, is based on an innovative technology called mRNA which is different from the technology that has been accepted for the development of vaccines so far. The company hopes for further growth with the development of additional vaccines, including influenza, but data from the company's Phase 1 trial released in December have disappointed investors.
At the same time, it was reported that Pfizer CEO Albert Burla expects the world to overcome the corona crisis and return to a "normal life" as early as next spring. Overcoming the stubborn virus that has disrupted life around the world in the last two years and caused the deaths of millions of people.The antiviral drug developed by Pfizer and intended for people at risk in the early stages of the disease manages to prevent deterioration to severe morbidity in 90% of risks, and help prevent deaths in the latest outbreak.
Articles Archive
Top Categories
ABOUT IFI TODAY
Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum